{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"10"},{"groupId":"OG012","value":"8"},{"groupId":"OG013","value":"7"},{"groupId":"OG014","value":"13"},{"groupId":"OG015","value":"11"},{"groupId":"OG016","value":"95"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"3"},{"groupId":"OG019","value":"5"},{"groupId":"OG020","value":"12"},{"groupId":"OG021","value":"23"},{"groupId":"OG022","value":"3"},{"groupId":"OG023","value":"7"},{"groupId":"OG024","value":"7"},{"groupId":"OG025","value":"8"},{"groupId":"OG026","value":"4"},{"groupId":"OG027","value":"6"},{"groupId":"OG028","value":"4"},{"groupId":"OG029","value":"6"},{"groupId":"OG030","value":"5"},{"groupId":"OG031","value":"30"},{"groupId":"OG032","value":"1"},{"groupId":"OG033","value":"15"},{"groupId":"OG034","value":"24"},{"groupId":"OG035","value":"24"},{"groupId":"OG036","value":"23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"13"},{"groupId":"OG011","value":"13"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"8"},{"groupId":"OG014","value":"14"},{"groupId":"OG015","value":"13"},{"groupId":"OG016","value":"107"},{"groupId":"OG017","value":"3"},{"groupId":"OG018","value":"3"},{"groupId":"OG019","value":"5"},{"groupId":"OG020","value":"13"},{"groupId":"OG021","value":"26"},{"groupId":"OG022","value":"3"},{"groupId":"OG023","value":"7"},{"groupId":"OG024","value":"10"},{"groupId":"OG025","value":"9"},{"groupId":"OG026","value":"4"},{"groupId":"OG027","value":"8"},{"groupId":"OG028","value":"4"},{"groupId":"OG029","value":"6"},{"groupId":"OG030","value":"5"},{"groupId":"OG031","value":"41"},{"groupId":"OG032","value":"1"},{"groupId":"OG033","value":"17"},{"groupId":"OG034","value":"25"},{"groupId":"OG035","value":"25"},{"groupId":"OG036","value":"25"}],"units":"Participants"}],"description":"An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology.\n\nAny worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.","groups":[{"description":"CC220 0.30mg","id":"OG000","title":"Cohort A: Treatment 1"},{"description":"CC220 0.45mg","id":"OG001","title":"Cohort A: Treatment 2"},{"description":"CC220 0.60mg","id":"OG002","title":"Cohort A: Treatment 3"},{"description":"CC220 0.75mg","id":"OG003","title":"Cohort A: Treatment 4"},{"description":"CC220 0.90mg","id":"OG004","title":"Cohort A: Treatment 5"},{"description":"CC220 1.0mg","id":"OG005","title":"Cohort A: Treatment 6"},{"description":"CC220 0.30mg + DEX","id":"OG006","title":"Cohort B: Treatment 1"},{"description":"CC220 0.45mg + DEX","id":"OG007","title":"Cohort B: Treatment 2"},{"description":"CC220 0.60mg + DEX","id":"OG008","title":"Cohort B: Treatment 3"},{"description":"CC220 0.75mg + DEX","id":"OG009","title":"Cohort B: Treatment 4"},{"description":"CC220 0.90mg + DEX","id":"OG010","title":"Cohort B: Treatment 5"},{"description":"CC220 1.0mg + DEX","id":"OG011","title":"Cohort B: Treatment 6"},{"description":"CC220 1.1mg + DEX","id":"OG012","title":"Cohort B: Treatment 7"},{"description":"CC220 1.2mg + DEX","id":"OG013","title":"Cohort B: Treatment 8"},{"description":"CC220 1.3.mg + DEX","id":"OG014","title":"Cohort B: Treatment 9"},{"description":"CC220 1.6mg + DEX","id":"OG015","title":"Cohort B: Treatment 10"},{"description":"CC220 + DEX","id":"OG016","title":"Cohort D: Treatment 1"},{"description":"CC220 1.0mg + DARA + DEX","id":"OG017","title":"Cohort E: Treatment 1"},{"description":"CC220 1.1mg + DARA + DEX","id":"OG018","title":"Cohort E: Treatment 2"},{"description":"CC220 1.2mg + DARA + DEX","id":"OG019","title":"Cohort E: Treatment 3"},{"description":"CC220 1.3mg + DARA + DEX","id":"OG020","title":"Cohort E: Treatment 4"},{"description":"CC220 1.6mg + DARA + DEX","id":"OG021","title":"Cohort E: Treatment 5"},{"description":"CC220 1.0mg + BORT + DEX","id":"OG022","title":"Cohort F: Treatment 1"},{"description":"CC220 1.1mg + BORT + DEX","id":"OG023","title":"Cohort F: Treatment 2"},{"description":"CC220 1.3mg + BORT + DEX","id":"OG024","title":"Cohort F: Treatment 3"},{"description":"CC220 1.6mg + BORT + DEX","id":"OG025","title":"Cohort F: Treatment 4"},{"description":"CC220 1.1mg + CFZ + DEX","id":"OG026","title":"Cohort G: Treatment 1"},{"description":"CC220 1.3mg + CFZ + DEX","id":"OG027","title":"Cohort G: Treatment 2"},{"description":"CC220 1.6mg + CFZ + DEX","id":"OG028","title":"Cohort G: Treatment 3"},{"description":"CC220 + DEX","id":"OG029","title":"Cohort H1"},{"description":"CC220 + DEX","id":"OG030","title":"Cohort H2"},{"description":"CC220 + DEX","id":"OG031","title":"Cohort I"},{"description":"CC220Vd 1.0mg + NE-ASCT","id":"OG032","title":"Cohort J1: Treatment 1"},{"description":"CC220Vd 1.6mg + NE-ASCT","id":"OG033","title":"Cohort J1: Treatment 2"},{"description":"CC220 1.0mg + DARA + DEX","id":"OG034","title":"Cohort K: Treatment 1"},{"description":"CC220 1.3mg + DARA + DEX","id":"OG035","title":"Cohort K: Treatment 2"},{"description":"CC220 1.6mg + DARA + DEX","id":"OG036","title":"Cohort K: Treatment 3"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who were treated with CC-220","reportingStatus":"POSTED","timeFrame":"Approximately on average of (Cohort A: 16.23 Cohort B: 10.32 Cohort D: 18.68 Cohort E: 15.65 Cohort F: 12.66 Cohort G: 16.03 Cohort H1: 17.22 Cohort H2: 21.07 Cohort I: 17.10 Cohort J: 20.56 Cohort K: 13.56) Months","title":"Number of Participants With Treatment Related Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}